TRANSPOD
22.7.2022 08:02:07 CEST | Business Wire | Press release
TransPod , the startup that is building the world’s leading ultra-high-speed ground transportation system (the TransPod Line ) to disrupt and redefine passenger and cargo transportation, unveiled the FluxJet, an industry-defining innovation that transforms the way we live, work, and travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005004/en/
Based on groundbreaking innovations in propulsion and fossil-fuel-free clean energy systems, the FluxJet is a fully electric vehicle that is effectively a hybrid between an aircraft and a train. Featuring technological leaps in contactless power transmission and a new field of physics called veillance flux , the FluxJet travels in a protected guideway at over 1000 km/h – faster than a jet and three times as fast as a high-speed train.
The FluxJet will operate exclusively on the TransPod Line, a network system with stations in key locations and major cities, featuring high-frequency departures designed to enable fast, affordable, and safe travel. Most recently, TransPod confirmed $550M US finance and announced the next phase of an $18B US infrastructure project to build the TransPod Line to connect the cities of Calgary and Edmonton in Alberta, Canada. Preliminary construction work, including the environmental impact assessment, has begun. This critical project will create up to 140,000 jobs and add $19.2B to the region’s GDP throughout construction. Once the TransPod Line is in operation, it will cost passengers approximately 44 per cent less than a plane ticket to travel the corridor and reduce CO2 emissions by 636,000 tonnes per year.
“All the hard work over the past few years has led to this milestone moment where talk is becoming a reality. The technology is proven, and we have the confidence of investors, governments, and partners to continue pushing forward to redefine transportation effectively,” said Sebastien Gendron, co-founder and CEO, TransPod.
At TransPod’s unveiling event in Toronto, a scaled-down FluxJet was featured in a live demonstration showing its flight capabilities. The almost 1-tonne FluxJet vehicle demonstrated a take-off, travel, and landing procedure within its guideway. Event and demo footage can be found here .
“This milestone is a major leap forward,” said Ryan Janzen, co-founder and CTO, TransPod. “The FluxJet is at a nexus of scientific research, industrial development, and massive infrastructure to address passengers' needs and reduce our dependence on fossil-fuel-heavy jets and highways.”
“TransPod completely changes the game with ultra high-speed, zero-emission passenger travel and freight transportation between major gateway cities,” said Yung Wu, CEO of MaRS Discovery District. “It is time for bold action from our policymakers, investors, and operators to support the commercialization of made-in-Canada innovations like TransPod, to win in the multi-trillion dollar global innovation economy."
“The FluxJet is a first for Canadian innovation and is the next great infrastructure project to be brought worldwide,” said Janzen. “The TransPod Line is being developed in collaboration with our partners in Europe, USA, and beyond, including universities, research centres, the aerospace industry, architecture, railway, and construction partners.”
TransPod’s FluxJet unveiling was made possible with the support and collaboration of the Building Trades of Alberta , Canada’s Building Trades Unions , Dassault Systèmes , DHL Express , MaRS , Ikos Consulting , REC Architecture , and SADE Engineering .
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading tube-transportation system (the TransPod Line ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada and has affiliate companies in Alberta, France, and the UAE. Visit www.transpod.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom